KR102690437B1 - 항-응고 인자 xi 항체 - Google Patents

항-응고 인자 xi 항체 Download PDF

Info

Publication number
KR102690437B1
KR102690437B1 KR1020197025752A KR20197025752A KR102690437B1 KR 102690437 B1 KR102690437 B1 KR 102690437B1 KR 1020197025752 A KR1020197025752 A KR 1020197025752A KR 20197025752 A KR20197025752 A KR 20197025752A KR 102690437 B1 KR102690437 B1 KR 102690437B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197025752A
Other languages
English (en)
Korean (ko)
Other versions
KR20190116990A (ko
Inventor
웬이 왕
취안 유
시아오우 리우
Original Assignee
상하이 베네마에 파머수티컬 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 베네마에 파머수티컬 코포레이션 filed Critical 상하이 베네마에 파머수티컬 코포레이션
Publication of KR20190116990A publication Critical patent/KR20190116990A/ko
Application granted granted Critical
Publication of KR102690437B1 publication Critical patent/KR102690437B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197025752A 2017-02-10 2017-12-29 항-응고 인자 xi 항체 Active KR102690437B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体
CN201710073984.X 2017-02-10
PCT/CN2017/119856 WO2018145533A1 (zh) 2017-02-10 2017-12-29 抗凝血因子xi抗体

Publications (2)

Publication Number Publication Date
KR20190116990A KR20190116990A (ko) 2019-10-15
KR102690437B1 true KR102690437B1 (ko) 2024-07-30

Family

ID=63107934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025752A Active KR102690437B1 (ko) 2017-02-10 2017-12-29 항-응고 인자 xi 항체

Country Status (9)

Country Link
EP (1) EP3581587B1 (enExample)
JP (1) JP7271430B2 (enExample)
KR (1) KR102690437B1 (enExample)
CN (1) CN108409863B (enExample)
AU (2) AU2017397778B2 (enExample)
BR (1) BR112019016300A2 (enExample)
CA (1) CA3054322A1 (enExample)
MX (1) MX2019009500A (enExample)
WO (1) WO2018145533A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
EP3914624A4 (en) * 2019-01-21 2022-10-19 Aronora, Inc. NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES
CN113474374B (zh) * 2019-04-16 2025-05-02 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN110498839A (zh) * 2019-09-19 2019-11-26 河南省农业科学院 氟罗沙星单链抗体关键多肽序列及应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TWI882142B (zh) * 2020-07-02 2025-05-01 大陸商北京拓界生物醫藥科技有限公司 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981754B2 (ja) * 1990-02-02 1999-11-22 第一化学薬品株式会社 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体
KR100925348B1 (ko) * 2001-06-12 2009-11-09 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항-혈액 응고 인자 ⅷ 항체
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (en) * 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR20190116990A (ko) 2019-10-15
MX2019009500A (es) 2020-01-30
JP7271430B2 (ja) 2023-05-11
EP3581587A1 (en) 2019-12-18
AU2025203303A1 (en) 2025-05-29
EP3581587A4 (en) 2021-03-31
CN108409863A (zh) 2018-08-17
AU2017397778A1 (en) 2019-10-03
WO2018145533A1 (zh) 2018-08-16
RU2019128423A3 (enExample) 2021-03-19
EP3581587B1 (en) 2025-02-05
CA3054322A1 (en) 2018-08-16
CN108409863B (zh) 2023-09-26
JP2020507578A (ja) 2020-03-12
AU2017397778B2 (en) 2025-03-06
BR112019016300A2 (pt) 2020-06-16
RU2019128423A (ru) 2021-03-10

Similar Documents

Publication Publication Date Title
KR102690437B1 (ko) 항-응고 인자 xi 항체
JP2022046656A (ja) 抗凝固因子ｘｉ抗体
JP2024054266A (ja) 組織因子経路インヒビター抗体およびその使用
CN102725309B (zh) 针对GPVI的新的拮抗剂抗体及其Fab片段及其用途
CN114478781B (zh) 抗凝血因子xi抗体
JP7022081B2 (ja) 抗凝固因子ｘｉ抗体
JP2019510474A (ja) トロンビン抗体、その抗原結合フラグメント及び医薬用途
RU2800719C2 (ru) Антитела к фактору xi
US11958911B2 (en) Anti-coagulation factor XI antibody
HK40075243A (en) Anticoagulant factor xi antibodies
HK40075243B (zh) 抗凝血因子xi抗体
WO2021032174A1 (zh) 一种抗cd47抗原结合蛋白及其应用
HK40075244A (en) Anticoagulant factor xi antibodies
HK40010556A (en) Anti-coagulation factor xi antibody
HK40075244B (zh) 抗凝血因子xi抗体
HK40057273A (en) Anti-factor xi antibodies
HK40057273B (zh) 抗凝血因子xi抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190902

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230403

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240222

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230403

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240222

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231004

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240527

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240522

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20240222

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20231004

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240726

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240726

End annual number: 3

Start annual number: 1

PG1601 Publication of registration